These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30206776)

  • 1. Golimumab in inflammatory bowel diseases: present and future scenarios.
    Dragoni G; Le Grazie M; Orlandini B; Rogai F
    Clin J Gastroenterol; 2019 Feb; 12(1):1-9. PubMed ID: 30206776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Golimumab: clinical update on its use for ulcerative colitis.
    Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
    Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab for the treatment of ulcerative colitis.
    Flamant M; Paul S; Roblin X
    Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
    Vande Casteele N; Khanna R
    Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on anti-TNF agents in ulcerative colitis.
    Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
    Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW; Fedorak RN
    Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP; Marín AC; McNicholl AG; Chaparro M
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Does conservative therapy of chronic inflammatory bowel diseases still play a role?].
    Seibold F
    Swiss Surg; 2003; 9(3):127-30. PubMed ID: 12815833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
    Pariente B; Laharie D
    Aliment Pharmacol Ther; 2014 Aug; 40(4):338-53. PubMed ID: 24957164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-TNF biologics in the treatment of chronic inflammatory bowel disease].
    Nikolaus S; Schreiber S
    Internist (Berl); 2008 Aug; 49(8):947-8, 950-3. PubMed ID: 18584139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.